ទំព័រដើម › ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ › ហ្វ្លរីដា › Miami
ការសាកល្បងគ្លីនិកសម្រាប់ ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ នៅក្នុង Miami, FL
ការសិក្សាចំនួន 24 សម្រាប់ ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Miami (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Miami Cancer Institute, Miami
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Miami Cancer Institute, Miami
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Miami Cancer Institute, Miami
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Miami Cancer Institute, Miami
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Miami Cancer Institute, Miami
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Nicklaus Children's Hospital, Miami
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Miami, Miami
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
កំពុងជ្រើសរើស
- University of Miami, Miami
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Bioresearch Partners, Miami
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Miami, Miami
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- University of Miami (peds), Miami
- Niklaus Children's Hospital, Miami
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Miami, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Miami, Miami
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of Miami Health System, Miami
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of Miami, Miami
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sylvester Comprehensive Cancer Center, Miami
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of Miami - Miller School of Medicine, Miami
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- University of Miami, Miami
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of Miami, Miami
ការសាកល្បងសម្រាប់ ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 85
- New York City, NYការសិក្សា 51
- Boston, MAការសិក្សា 44
- Baldwin Park, CAការសិក្សា 40
- Seattle, WAការសិក្សា 40
- Columbus, OHការសិក្សា 35
- Philadelphia, PAការសិក្សា 34
- Durham, NCការសិក្សា 33
- Atlanta, GAការសិក្សា 30
- Tampa, FLការសិក្សា 29
- Chicago, ILការសិក្សា 26
- Portland, ORការសិក្សា 25
ការសិក្សាផ្សេងទៀតនៅក្នុង Miami
- មហារីកទ្រូងការសិក្សា 42
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 36
- Non-Small Cell Lung Cancerការសិក្សា 31
- មហារីកតូចការសិក្សា 27
- ជំងឺធាត់ការសិក្សា 27
- មហារីកដែលរីករាលដាលការសិក្សា 24
- មហារីកស៊ុតការសិក្សា 23
- ទម្ងន់លើសការសិក្សា 23
- ជំងឺ Multiple Myelomaការសិក្សា 21
- ជំងឺរលាកពោះវៀនធំមានស្នាមការសិក្សា 21
- ជំងឺអាល់ហ្សៃមែរការសិក្សា 20
- មហារីកសួតការសិក្សា 20
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 5 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។